Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck

Patricia A. Tang, Lillian L. Siu, Eric X. Chen, Sebastien J. Hotte, Stephen Chia, James K. Schwarz, Gregory R. Pond, Caitlin Johnson, A. Dimitrios Colevas, Timothy W. Synold, Lakshmi S. Vasist, Eric Winquist

Research output: Contribution to journalArticlepeer-review

58 Scopus citations

Abstract

Ispinesib (SB-715992) inhibits the mitotic kinesin spindle protein (KSP), a novel target for anticancer therapy. A phase II study was conducted to examine the efficacy of ispinesib in recurrent or metastatic head and neck squamous cell carcinoma (RMHNSC). Patients with up to one prior line of chemotherapy for RMHNSC were treated with ispinesib 18 mg/m2 IV over 1 hour every 21 days. Twenty-one patients were enrolled onto this study with a target stage I sample size of 19. Of 20 evaluable patients, no objective responses were seen and stable disease > 2 cycles was observed in five patients (25%). The median time to progression was 1.4 (95% CI 1.3-2.3) months, median survival was 3.5 (95% CI 2.8-7.8) months, and 1 year overall survival was 20% (95% CI 8.3-48.1%). The most frequent attributable grades III-V adverse events were neutropenia (60% of patients) and leukopenia (55%). The pharmacokinetic profile was consistent with results from phase I studies. Archival tissues (n = 14) demonstrated low to moderate KSP expression by immunohistochemistry. In addition, no pharmacodynamic changes were observed in peripheral blood mononuclear cells. We detected no antitumor activity of ispinesib in RMHNSC on this dosing schedule.

Original languageEnglish (US)
Pages (from-to)257-264
Number of pages8
JournalInvestigational New Drugs
Volume26
Issue number3
DOIs
StatePublished - Jun 2008

Keywords

  • Head and neck neoplasms
  • Ispinesib
  • Kinesin spindle protein
  • Phase II
  • Squamous
  • hsEg5

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck'. Together they form a unique fingerprint.

Cite this